Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/Kumetrix

This article was originally published in The Gray Sheet

Executive Summary

Bayer will evaluate Kumetrix' silicon micro-needle technology for application in diabetic blood glucose monitoring over the next two to four months under an exclusive agreement. A hand-held meter using a micro-needle "the size of a human hair" is currently in pilot clinical studies at Kumetrix and uses a blood sample 1/100th the size of a drop of blood to make sampling "painless," Kumetrix claims. Additional agreements between Bayer and Union City, California-based Kumetrix would be needed for development and licensing of the technology for commercial use, assuming a positive initial evaluation by Bayer
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013293

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel